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Abstract
Background: Insulin-like growth factor-1 (IGF-1) is important in normal growth, development, and homeostasis.
Current use of oral contraceptives (OC) decreases IGF-1 concentrations; however, the effect of past use, age/timing
of use, and type of OC used on IGF-1 levels is unknown. OC are the most commonly used form of birth control
worldwide. Both IGF-1 and OC use have been linked to premenopausal breast and colorectal cancers, osteoporosis
and cardiovascular disease (CVD). Understanding the effects of different patterns of OC use on IGF-1 levels may
offer insight into its influence on disease risk in young women.
Methods: In a cross-sectional study of 328 premenopausal women ages 18 to 21 and 31 to 40 we examined the
relationship between different patterns of OC use and circulating IGF-1 using adjusted linear regression analysis.
Information on OC use was obtained through an interviewer administered questionnaire. Plasma IGF-1 was
assessed with enzyme linked immunosorbent assay (ELISA).
Results: Among women aged 18 to 21, ever OC use was significantly associated with decreased IGF-1 levels
compared to never use (b = -57.2 ng/ml, 95% confidence interval (CI): -88.7, -25.8). Among women aged 31 to 40,
past users who first used OC at 25 years of age or older (b = 43.8 ng/ml, 95% CI: 8.8, 78.8), in the last 15 years (b =
35.1 ng/ml, 95% CI: 9.3, 61.0) or after 1995 (b = 46.6 ng/ml, 95% CI: 13.4, 79.8) had significantly higher IGF-1 levels
compared to never users.
Conclusion: This is the first study to highlight the long term effects of OC use after cessation on IGF-1 levels
among premenopausal women, which previously were thought to be transitory. Future studies of past use and
IGF-1 levels are required and must consider age/timing of use and type/generation of OC used. Additional studies
are needed to confirm the potential mediation of IGF-1 levels in the links between OC use and health outcomes.
Background
Insulin-like growth factor-I (IGF-I) is a growth hormone
(GH) dependent peptide produced primarily in the liver,
but it is also produced locally by many other tissues and
can act in an autocrine and paracrine manner as well as
through endocrine pathways [1]. IGF-1 plays an impor-
tant role in physiological growth, development and
homeostasis. Circulating IGF-1 concentrations have
been used as an indicator of the total pool of IGF-1
available to cells and as a reflection of inter-individual
differences in IGF-1 tissue bioactivity [2].
The relationship between circulating IGF-1 levels and
disease risk among women is complex as studies have
shown that IGF-1 can be either positively (e.g. cancer)
or negatively (i.e. osteoporosis, heart disease) associated
with adverse health outcomes [3-11]. In both normal
and neoplastic cells IGF-1 regulates cell proliferation,
mitogenesis and apoptosis [12] and high IGF-1 levels
have been associated with approximately twice the risk
of developing premenopausal breast cancer and with a
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cer [3-7]. IGF-I is also critical for long bone growth and
skeletal maturation and in adulthood it helps to main-
tain bone mass and density [13]. Among postmenopau-
sal women, high IGF-1 levels are associated with a
reduced risk of osteoporotic fractures; a positive correla-
tion between serum IGF-1 levels and bone mineral den-
sity is also evident [8,9]. In the heart, IGF-1 delays
cardiomyocyte apoptosis, affects myocardial contractility,
and participates in the inflammation linked angiogenesis
and repair processes following ischaemic events [14].
Consequently, high IGF-1 levels have been associated
with a reduced risk of both ischemic heart disease
(IHD) and ischemic stroke (IS) [10,11,14].
Because of the role IGF-1 plays in health and disease,
there has been a growing interest in understanding fac-
tors that influence IGF-1 levels [15-17]. Age is a strong
predictor of circulating IGF-1; ethnicity, anthropometric
indices (body mass index (BMI), weight, height), physical
activity, smoking, alcohol and diet can also affect IGF-1
levels [15,17-22]. A small number of studies have exam-
ined the effect of current use of oral contraceptives (OC)
on IGF-1 concentrations; when compared to never users
current users have significantly lower IGF-1 levels
[23-25]. However, the effect of other patterns of OC use,
in particular past use and timing of use during life on cir-
culating IGF-1 has not been studied. These patterns may
influence IGF-1 levels over the longer term and thus also
impact IGF-1 related health outcomes. In addition, many
earlier studies had limitations such as small study sam-
ples and failure to control for factors known to influence
circulating IGF-1, such as age, BMI and ethnicity [23-25],
thereby limiting current knowledge of the relationship
between OC use and IGF-1 levels.
We examined the association between other patterns
of use not measured in earlier studies, such as past use,
and plasma IGF-1 levels among 328 premenopausal
women aged 18 to 21 and 31 to 40. The association
between the generation of OC (i.e. 2
nd versus 3
rd)
women likely used and IGF-1 was also explored.
Numerous studies have shown an association between
OC use and risk of breast and colorectal cancers, osteo-
porosis and cardiovascular disease (CVD) [26-37]. IGF-1
is a key player in health and disease and a few studies
have suggested a relationship between OC use and IGF-
1 levels. Hence, understanding how OC use affects cir-
culating IGF-1 may provide insight into whether the
relationship between OC use and disease risk may in
part be mediated by the IGF-1 pathway.
Methods
Recruitment of study population and data collection
The women in this analysis were initially recruited for a
previously completed study [38]. In the earlier study a
total of 368 women were recruited in Toronto, Canada
from July 2005 to July 2008 through advertising at local
universities, hospitals, community centres and newspa-
pers. Women were recruited into two groups: those
aged 18 to 21 who were nulliparous (n = 200) and those
aged 31 to 40 who were either nulliparous or parous (n
= 168). Of the 368 women recruited, 40 women were
excluded because of 1) missing IGF-1 values (n = 4); 2)
missing information on the date of their last menstrual
period (n = 9); 3) not having had a menstrual period
within 42 days among 18 to 21 year olds (n = 5) and
within 35 days among 31 to 40 year olds (n = 1) [39]; 4)
missing information regarding OC use (n = 21). This
left a total of 328 women for the present analysis: 180
women aged 18 to 21 years and 148 women aged 31 to
40 years. At a single study visit for each woman we
measured her height, weight and a blood sample was
drawn. Information on OC use and other variables was
obtained through an interviewer administered question-
naire. Women were asked if they had ever used OC, the
age at which they initiated and/or discontinued use
(where applicable), and if they were currently using OC.
All procedures were reviewed and approved by the
Research Ethics Boards of Mount Sinai Hospital and the
University Health Network and participating women
provided informed consent.
IGF-1 assay
For each woman an aliquot of plasma was thawed and
IGF-1 was assessed with enzyme linked immunosorbent
assay (ELISA) using the DSL total IGF-1 kit (DSL-10-
2800). Intra-assay coefficients of variation were 5% to
9%; inter-assay coefficients of variation were 9% to 11%.
Data Analysis
The effect of OC use (ever vs. never) on IGF-1 levels
differed according to age group (18 to 21 years vs. 31 to
40 years) (P for interaction = 0.005). Consequently, we
assessed the relationship between different patterns of
OC use and IGF-1 levels separately in women aged 18
to 21 and women aged 31 to 40 using linear regression.
The patterns of OC use considered in each age group
were: ever vs. never use; current vs. past vs. never use;
age (years) at first use (for ages 18 to 21: 10 to 15; 16 to
18; 19 to 21; for ages 31 to 40: <= 18; 19 to 24; 25+);
duration (years) of use (for ages 18 to 21: < 1; 1 to 2; >
2; for ages 31 to 40: < 5; 5 to 9; 10+); and time (years)
since last use (for ages 18 to 21: Current; < 1; 1+; for
ages 31 to 40: Current, < 5; 5 to 9; 10+). Among women
aged 31 to 40 we also considered time (years) since first
use (< 15; 15 to 19; 20+) and year of first use (1979 to
1994; 1995-2004). Women who reported ever using OC
(at least one month of use) were considered ever users.
Among ever users, women using OC at the time of their
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stopped using OC prior to their study visit were consid-
ered past users. For analyses including women ages 18
to 21 years, the following confounders were included in
the adjusted models as independent variables: age (age
18 vs. older) and ethnicity (East Asian, South Asian,
Other/Mixed vs. European). Among women 31 to 40
years old, adjusted models included the following con-
founders as independent variables: weight (75
th percen-
tile and above vs. below), current physical activity (ever
doing an activity at least once per week vs. never) and
the number of days since their last menstrual period (<=
14 vs. > 14). These confounders were selected as they
showed some association with IGF-1 levels in unad-
justed analyses. All tests were two-sided with P <0 . 0 5
as the criterion for significance. All analyses were con-
ducted using SAS version 9.2.
Results
Table 1 displays the characteristics of the study popula-
tion. Mean IGF-1 levels were significantly higher among
younger women compared to older women (P < 0.0001).
The majority of women aged 18 to 21 were either East
Asian or Caucasian, while the majority of women aged
31 to 40 were Caucasian. Younger women were more
likely to report never use of OC, whereas older women
were more likely to report past use.
Table 2 shows unadjusted IGF-1 levels according to
different characteristics for women aged 18 to 21 and
women aged 31 to 40. Among women aged 18 to 21,
IGF-1 levels were significantly higher in women aged 18
years old compared to those aged 19 to 21 years old.
IGF-1 levels were lowest among East Asians and women
of Other/Mixed ancestry compared to Europeans and
South Asians and the difference across groups
approached significance. Among women aged 31 to 40
years, women who were in the highest quartile of weight
had lower IGF-1 levels compared to those in the lower
three quartiles and the difference across groups was sig-
nificant. Women who reported currently doing any phy-
sical activity at least once per week had significantly
higher IGF-1 levels compared to those who did not.
IGF-1 levels were also significantly higher in the luteal
phase of the menstrual cycle (> 14 days since the last
menstrual period) compared to the follicular phase.
The results of linear regression analysis for the rela-
tionship between different patterns of OC use and IGF-
1 levels for women aged 18 to 21 and women aged 31
to 40 are shown in Tables 3 and 4, respectively. Among
women 18 to 21 years of age, those who ever used OC,
either past or current users, had significantly lower IGF-
1 levels compared to those who never used them.
Among those who ever used OC, we observed no rela-
tionship between age at first use, time since last use or
total duration of use and IGF-1 levels. In the adjusted
model, ever use of OC explained approximately 9%
(adjusted R-square (R
2) = 0.09) of the total variation in
IGF-1 levels in this age group.
Among women aged 31 to 40, current and never users
had similar IGF-1 levels. Past users who first reported
using OC at the age of 25 years or older and/or more
recently (in the last 15 years or starting in 1995 or later)
had the highest IGF-1 levels compared to never users.
There was no association between IGF-1 levels and
duration of use or time since last use in past users. In
adjusted analyses comparing never vs. past vs. current
users, OC use explained approximately 4% (adjusted R
2
= 0.04) of the total variation in IGF-1 levels in this age
group, with a maximum adjusted R
2 of 0.09 when con-
sidering time since 1
st use in past users compared to
never users. We observed no relationship between IGF-
1 levels and different patterns of OC use among current
users when compared to never users (data not shown).
Figure 1 displays unadjusted IGF-1 levels according to
year of first and last use among past users and accord-
ing to year of first use among current users. We used
Table 1 Characteristics of the study population, women
aged 18 to 21 years and aged 31 to 40 years
Ages 18 to 21
(n = 180)
Ages 31 to 40
(n = 148)
Mean
(SD)
Range Mean
(SD)
Range
IGF-1 (ng/ml) 315.4
(104.1)
94.0 -
620.0
174.4
(56.7)
33.0 -
314.0
Age (years) 19.7 (1.1) 18 - 21 35.3 (3.1) 31 - 40
BMI (kg/m
2) 23.3 (4.2) 17.5 - 48.9 25.6 (5.5) 17.4 - 50.8
Height (cm) 162.8 (6.9) 146.0 -
183.0
162.7
(5.7)
145.0 -
175.0
Weight (kg) 62.0 (13.7) 44.6 -
139.6
67.9
(15.0)
44.0 -
135.1
Days since last period 16.7 (9.7) 1.0 - 41.0 15.9 (8.9) 1.0 - 35.0
Ethnicity n(%)
European 69 (39) 97 (65)
East Asian 56 (31) 11 (7)
South Asian 17 (10) 7 (5)
Other/Mixed
a 37 (21) 34 (23)
Parous n(%) 0 (0) 36 (24)
OC use n(%)
Never 100 (56) 37 (25)
Past 29 (16) 88 (59)
Current 51 (28) 24 (16)
Ever physical activity n
(%)
b
Childhood 169 (94) 127 (85)
Teenage 149 (83) 118 (79)
Current 129 (72) 126 (85)
a Includes African, Caribbean, Middle Eastern, First Nation, Latin American;
b
Doing physical activity at least once per week
Blackmore et al. BMC Women?’?s Health 2011, 11:15
http://www.biomedcentral.com/1472-6874/11/15
Page 3 of 9year as a proxy for the type of OC women may have
used. Among past users, those who first used OC from
1995 onward had significantly higher IGF-1 levels com-
pared to both groups of women who first used OC prior
to 1995 (P = 0.02). A similar pattern was observed
among current users, but the difference in IGF-1 levels
was not significant (P = 0.11). IGF-1 levels of ever users
(past or current) who only used OC 1995 or later were
also significantly higher compared to ever users who
used OC before 1995 at some point (207.7 ng/ml vs.
170.5 ng/ml, P = 0.008).
Discussion
The relationship between OC use and plasma IGF-1 levels
differed between women ages 18 to 21 and women ages
31 to 40. Women in the younger age group who reported
ever using OC had significantly lower IGF-1 levels com-
pared to never users. Among older women, past users of
Table 2 IGF-1 levels (ng/ml) for women aged 18 to 21 years and women aged 31 to 40 years according to different
characteristics
Ages 18 to 21 (n = 180) Ages 31 to 40 (n = 148)
No. Mean (SD) P* No. Mean (SD) P*
Age 0.002 0.76
18 32 366.9 (121.5) 31 to 35 81 175.7 (61.0)
19 to 21 148 304.3 (96.9) 36 to 40 67 172.8 (51.4)
BMI (kg/m
2) 0.36 0.12
< 20.0 33 312.1 (93.8) < 25.0 82 178.8 (55.2)
20.0 - 24.9 107 323.6 (109.3) 25.0 - 29.9 41 178.8 (62.7)
≥ 25.0 40 296.3 (97.4) ≥ 30.0 25 152.9 (47.9)
Height (cm) 0.67 0.92
≤ 158.5 52 311.3 (109.8) ≤ 159.5 39 176.2 (61.8)
158.6 - 162.4 42 322.6 (101.2) 159.6 - 163.0 46 174.6 (56.8)
162.5 - 167.4 43 327.2 (102.6) 163.1 - 167.0 35 168.9 (46.7)
≥ 167.5 43 301.7 (103.1) ≥ 167.1 28 178.5 (63.0)
Weight (kg) 0.14 0.02
≤ 53.5 44 316.3 (101.6) ≤ 57.9 35 170.4 (48.8)
53.6 - 59.3 47 301.1 (95.6) 58.0 - 64.4 37 186.7 (62.0)
59.4 - 66.3 45 344.6 (122.2) 64.5 - 73.4 40 186.7 (52.5)
≥ 66.4 44 300.0 (91.6) ≥ 73.5 36 152.1 (57.6)
Ethnicity 0.08 0.90
European 69 327.2 (112.8) European 96 172.7 (54.6)
East Asian 56 304.3 (108.6) East Asian 11 186.1 (84.7)
South Asian 17 357.9 (92.9) South Asian 7 171.4 (50.0)
Other/Mixed
a 37 288.8 (76.4) Other/Mixed
a 34 176.2 (55.3)
Parity 0.49
Nulliparous 180 - Nulliparous 112 176.3 (57.5)
Parous 0- Parous 36 168.7 (54.7)
Physical Activity
b
Childhood 0.29 0.17
Never 11 283.3 (81.5) Never 22 159.1 (64.0)
Ever 169 317.5 (105.3) Ever 126 177.1 (55.2)
Teenager 0.68 0.98
Never 31 322.4 (103.1) Never 31 174.2 (60.6)
Ever 149 314.0 (104.6) Ever 117 174.5 (55.9)
Current 0.78 0.04
Never 50 319.2 (116.6) Never 23 151.9 (60.8)
Ever 129 314.3 (99.7) Ever 125 178.6 (55.2)
Days since last period 0.77 0.02
≤ 14 72 312.6 (100.9) ≤ 14 66 162.1 (50.7)
>14 108 317.3 (106.7) >1 4 82 184.4 (59.6)
* Results of t-test, one-way ANOVA (where applicable);
a Includes African, Caribbean, Middle Eastern, First Nation, Latin American;
b Doing physical activity at least
once per week
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never and current users. Past users ages 31 to 40 who first
used OC at 25 years of age or older and/or more recently
(15 years ago or less; from 1995 onward) had the highest
IGF-1 levels. Among older women the type of OC they
may have used (i.e. 2
nd vs. 3
rd generation) influenced IGF-
1 levels differently, with 3
rd generation OCs (introduced
around 1995) [40] resulting in higher IGF-1 levels among
both past and current users.
Previous studies of OC use and IGF-1 levels found
lower circulating IGF-1 in current users, consistent with
our findings among women ages 18 to 21 years. Among
311 women ages 17 to 35, current users had signifi-
cantly lower plasma IGF-1 levels compared to non-users
[23]. Similarly, in two smaller studies, women currently
taking OC (n = 9, mean age 25.8 years) had significantly
lower plasma IGF-1 levels compared to women receiving
no medication (n = 10, mean age 31.0 years) [24] and 18
women compared before and after intake of either of
two OC formulations over 21 days had significant
reductions in IGF-1 levels [25].
Conversely, among women ages 31 to 40 we found
that those who first used OC in adulthood and/or more
recently and then stopped had increased IGF-1 levels
compared to never and current users. To our knowl-
edge, our study is the first to consider past use of OC
and other patterns of OC use and IGF-1 levels in pre-
menopausal women and suggests a potential long term
effect of past use of OC on IGF-1 depending on when
they are first started. The mechanism by which OC sup-
press circulating IGF-1 in current users is likely a phar-
macological effect resultin gf r o mh e p a t i ce x p o s u r et o
the estrogen component delivered via the portal circula-
tion [24]. These effects are believed to be transitory and
no long-term effects on the IGF-1 axis have been
reported to date [15], but no longitudinal studies have
examined the relationship between past use of OC and
IGF-1. Also women who started taking OC at an older
age and/or more recently may have done so for different
reasons than women taking them at a younger age and
this may in part explain the effect of past use at an
older age on IGF-1 levels in this age group.
The effect of past use of OC on IGF-1 levels in older
women may also be influenced by the type (generation)
of OC they were using. Only two studies have consid-
ered the effect of different OC formulations on IGF-1
Table 3 Results of linear regression analysis (unadjusted and adjusted) for the relationship between patterns of oral
contraceptive use and IGF-1 levels (ng/ml) for women aged 18 to 21 years
Unadjusted Adjusted
a
No. Mean (SD) Beta 95%CI P Beta 95%CI P
OC Use
Never 100 336.8 (111.5) Reference 0.002 Reference 0.0004
Ever 80 288.7 (87.6) -48.1 -78.2, -18.0 -57.2 -88.7, -25.8
Never 100 336.8 (111.5) Reference 0.007 Reference 0.002
Past 29 295.6 (82.8) -41.2 -83.6, 1.2 -51.7 -94.6, -8.8
Current 51 284.7 (90.8) -52.1 -86.6, -17.5 -60.2 -95.5, -24.9
Ever Users
Age at first use
10 to 15 years 11 316.6 (103.4) 43.1 -23.2, 109.3 0.44 34.2 -36.7, 105.0 0.61
16 to 18 years 50 288.3 (87.9) 14.7 -32.4, 61.8 17.4 -44.7, 54.1
19 to 21 years 19 273.6 (77.2) Reference Reference
Time since last use
Current 51 284.7 (90.8) Reference 0.67 Reference 0.60
< 1 year 11 310.6 (29.3) 25.9 -32.5, 84.3 28.7 -30.0, 87.4
≥ 1 year 18 286.4 (102.7) 1.7 -46.5, 49.9 -1.7 -50.8, 47.5
Total duration of use
< 1 year 12 273.6 (78.8) -14.8 -76.3, 46.6 0.80 -11.8 -77.3, 53.7 0.82
1 to 2 years 42 293.2 (86.7) 4.7 -39.2, 48.7 7.0 -37.6, 51.6
>2 years 26 288.4 (95.1) Reference Reference
a Adjusted for age (18 vs. 19 to 21) and ethnicity (East Asian, South Asian, Other/Mixed vs. European)
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ship between the average daily estrogen dose and IGF-1
levels, although no association was found between the
type of progesterone and IGF-1 levels [23]. Conversely,
in a short-term study in a small number of women, a
greater reduction in mean plasma IGF-1 concentrations
was found in women taking an OC formulation contain-
ing a third generation versus second generation proges-
terone [25]. In the present study, past users starting at a
younger age most likely would have used second genera-
tion OC (introduced in the 1970s), at least initially,
while those starting at an older age most likely would
Table 4 Results of linear regression analysis (unadjusted and adjusted) for the relationship between patterns of oral
contraceptive use and IGF-1 levels (ng/ml) for women aged 31 to 40 years
Unadjusted Adjusted
a
No. Mean (SD) Beta 95%CI P Beta 95%CI P
OC Use
Never 37 167.2 (58.7) Reference 0.37 Reference 0.30
Ever 111 176.8 (56.1) 9.6 -11.7, 30.9 10.8 -9.7, 31.3
Never 37 167.2 (58.7) Reference 0.18 Reference 0.09
Past 87 181.4 (56.9) 14.2 -7.7, 36.1 16.4 -4.7, 37.6
Current 24 160.2 (51.1) -7.0 -36.3, 22.2 -7.7 -35.6, 20.2
Age at first use
Never 37 167.2 (58.7) Reference 0.04 Reference 0.04
Current 24 160.2 (51.1) -7.0 -35.8, 21.7 -7.8 -35.4, 19.8
Past
≤ 18 years 47 168.8 (52.7) 1.4 -22.5, 25.7 5.5 -17.8, 28.9
19 to 24 years 28 188.8 (61.0) 21.5 -5.9, 49.0 22.5 -4.2, 49.1
≥ 25 years 12 213.8 (50.6) 46.5 10.1, 83.0 43.8 8.8, 78.8
Time since first use
Never 37 167.2 (58.7) Reference 0.01 Reference 0.03
Current 24 160.2 (51.1) -7.0 -35.4, 21.3 -7.5 -35.0, 19.9
Past
≥ 20 years 25 156.0 (47.4) -11.3 -39.3, 16.8 -1.4 -29.3, 26.4
15 to 19 years 32 179.2 (54.5) 12.0 -14.2, 38.1 11.8 -13.7, 37.4
< 15 years 30 205.0 (58.4) 37.8 11.2, 64.4 35.1 9.3, 61.0
Time since last use
Never 37 167.2 (58.7) Reference 0.35 Reference 0.30
Current 24 160.2 (51.1) -7.0 -36.4, 22.3 -7.7 -35.8, 20.4
Past
<5 years 26 183.0 (58.1) 15.7 -12.9, 44.4 14.4 -13.0, 42.0
5 to <10 years 29 188.3 (61.9) 21.1 -6.7, 48.8 20.7 -6.1, 47.6
≥ 10 years 32 173.9 (51.7) 6.7 -20.3, 33.8 14.2 -12.0, 40.5
Duration of use
Never 37 167.2 (58.7) Reference 0.23 Reference 0.22
Current 24 160.2 (51.1) -7.0 -36.3, 22.2 -7.7 -35.7, 20.3
Past
<5 years 21 197.0 (65.2) 29.8 -0.7, 60.2 25.8 -3.6, 55.2
5 to < 10 years 33 178.6 (50.2) 11.4 -15.3, 38.1 16.3 -9.5, 42.0
≥ 10 years 33 174.3 (57.4) 7.1 -19.6, 33.8 10.2 -15.7, 36.2
Year of first use
Never 37 167.2 (58.7) Reference 0.03 Reference 0.02
Current 24 160.2 (51.1) -7.0 -35.9, 21.8 -8.1 -35.6, 19.4
Past
1979 to 1994 73 175.4 (54.8) 8.2 -14.0, 30.4 10.8 -10.6, 32.2
1995 to 2004 14 212.9 (59.2) 45.6 11.1, 80.1 46.6 13.4, 79.8
a Adjusted for current weight (75
th percentile and above vs. below), days since last reported menstrual cycle (<=14 vs. >14), and current physical activity at least
once per week (ever vs. never)
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[40]. Second and third generation OC contain a lower
estrogen dose compared to earlier formulations, but are
different from each other in the type of progesterone
they contain (androgenic vs. non-androgenic progesto-
gen, respectively) [25]. Contrary to earlier findings [25]
we found that both past and ever users who likely used
second generation OC (< 1995) had lower IGF-1 levels
compared to past and ever users who likely used third
generation OC (1995 or later). The effects of OC on cir-
culating IGF-1 could be due to a number of factors in
combination, including age at use, OC formulation, and
current vs. past use.
Oral contraceptives are the most commonly used form
of birth control by women worldwide [40]. However,
their use has been linked to premenopausal breast and
colorectal cancers, osteoporosis and CVD [26-37]. Cur-
rent and recent use (1 to 9 years since last use) and an
earlier age at first use (< 20 years) have been associated
with an increased risk of breast cancer [26-28], while
ever use of OC is associated with a reduced risk of col-
orectal cancer [29,30]. Studies in adolescent girls and
premenopausal women suggest that current OC use has
detrimental effects on bone mineral density, while stu-
dies of past use in peri/post-menopausal women suggest
a benefit of OC on bone health, although some studies
show no effect [31-33]. An increased risk of CVD has
been reported with current OC use compared to non-
current and never use; a small number of studies have
found a decreased risk or no risk with past use when
compared to never use [34-37].
Based on the findings of the present study and ear-
lier ones, could the relationship between OC use and
disease risk be at least in part mediated by the IGF-1
pathway? IGF-1 is positively associated with breast
and colorectal cancers in some studies [3-7]. With
respect to the positive association between OC use
and breast cancer [26-28], if mediated through IGF-1,
we would expect IGF-1 levels to be higher in current
or recent users and/or women who started OC at a
younger age. However, our results do not support this
hypothesis. It is also unlikely that IGF-1 plays a role
in the link between OC use and colorectal cancer risk
as we would anticipate lower IGF-1 levels in past
users who have a lower risk of colorectal cancer
[29,30]. It should be noted that the relationship
between 3
rd generation OC and breast and colorectal
cancer has not yet been evaluated and may differ
from relationships with older formulations. The rela-
tionship between OC use and CVD may, however, be
mediated by IGF-1. Increased risk of CVD is asso-
ciated with both current OC use and lower IGF-1
Current (n = 19)  Current (n = 5)  Past (n = 14)  Past (n = 23)  Past (n = 50) 
151.5 ng/ml  
193.0 ng/ml  
212.9 ng/ml  
172.7 ng/ml   176.6 ng/ml  
1
st use < 1995 
1
st use  1995 
 
1
st/Last use 
< 1995  
1
st use < 1995 
Last use  1995  
1
st/Last use 
 1995  
Oral Contraceptive Use 
Figure 1 Unadjusted mean IGF-1 levels (ng/ml) according to year of first use among past and current users of oral contraceptives
aged 31 to 40 years.
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Page 7 of 9levels [10,11,34-37] and our results confirm reduced
IGF-1 levels in current OC users. Decreased CVD risk
with past OC use [34-37] may be due to higher IGF-1
levels in former users as weo b s e r v e d .L o w e rI G F - 1
levels among current users may also potentially lead
to decreased bone mineral density, particularly in
young women, while the higher levels we observed in
older past users may decrease osteoporosis risk,
reflecting observed relationships between IGF-1, bone
density and osteoporosis [8,9,13].
The limitations of our study include the lack of
detailed information on the formulation of OC used,
which may have contributed to the low R
2,t h er e a s o n s
for starting and stopping OC, and missing information
on some potential confounders including smoking and
alcohol use. Strengths include the larger number of
w o m e nc o m p a r e dt om o s tp r e v i o u ss t u d i e sa n dt h e
availability of detailed inf o r m a t i o no nt h et i m i n go f
initiation and cessation of OC. Few studies have
addressed the potential effects of past use of OC or the
type/generation of OC used.
Conclusions
Our study is the first to demonstrate the long term
effects of OC after cessation on IGF-1 levels, particularly
in premenopausal women. It also highlights the impor-
tance of considering the timing of OC use during life
and the type/generation of OC used in future studies of
the health effects of OC use. Additional studies are
needed to confirm the potential mediation of IGF-1
levels in the links between OC use and adverse health
outcomes, such as CVD and osteoporosis.
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